Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
$149.95
-1.4%
$140.94
$107.43
$153.01
$6.29B0.792.14 million shs2.96 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$26.83
-2.5%
$25.92
$23.15
$59.73
$10.75B2.0112.07 million shs10.05 million shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
-1.38%-0.70%+6.61%+13.95%+4.76%
Moderna, Inc. stock logo
MRNA
Moderna
-2.54%-5.83%+10.37%-20.24%-54.42%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
$149.95
-1.4%
$140.94
$107.43
$153.01
$6.29B0.792.14 million shs2.96 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$26.83
-2.5%
$25.92
$23.15
$59.73
$10.75B2.0112.07 million shs10.05 million shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
-1.38%-0.70%+6.61%+13.95%+4.76%
Moderna, Inc. stock logo
MRNA
Moderna
-2.54%-5.83%+10.37%-20.24%-54.42%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
2.66
Moderate Buy$149.95N/A
Moderna, Inc. stock logo
MRNA
Moderna
2.00
Hold$41.8155.84% Upside

Current Analyst Ratings Breakdown

Latest MRNA and IBB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/10/2025
Moderna, Inc. stock logo
MRNA
Moderna
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$31.00 ➝ $32.00
10/8/2025
Moderna, Inc. stock logo
MRNA
Moderna
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/27/2025
Moderna, Inc. stock logo
MRNA
Moderna
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
8/22/2025
Moderna, Inc. stock logo
MRNA
Moderna
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetUnderperform$18.00 ➝ $15.00
8/4/2025
Moderna, Inc. stock logo
MRNA
Moderna
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetEqual Weight$40.00 ➝ $31.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$32.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$26.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$40.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingEqual Weight$32.00
7/22/2025
Moderna, Inc. stock logo
MRNA
Moderna
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetUnderperform$26.00 ➝ $25.00
(Data available from 10/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
N/AN/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
$3.24B3.24N/AN/A$28.33 per share0.95
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
N/AN/A0.00N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$7.53N/AN/AN/A-94.31%-25.96%-20.09%11/6/2025 (Estimated)

Latest MRNA and IBB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/6/2025Q3 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$1.95N/AN/AN/A$893.29 millionN/A
8/1/2025Q2 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.99-$2.13+$0.86-$2.13$116.26 million$142.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
$0.270.18%N/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A

Latest MRNA and IBB Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
9/15/2025
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
quarterly$0.08280.24%9/16/20259/16/20259/19/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
N/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/A
3.93
3.77

Institutional Ownership

CompanyInstitutional Ownership
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
62.45%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%

Insider Ownership

CompanyInsider Ownership
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
N/A
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
N/A41.40 millionN/AOptionable
Moderna, Inc. stock logo
MRNA
Moderna
5,800390.58 million347.62 millionOptionable

Recent News About These Companies

4 Analysts Assess Moderna: What You Need To Know
Moderna (NASDAQ:MRNA) Given Sell (E+) Rating at Weiss Ratings
Moderna, Inc. (NASDAQ:MRNA) Given Average Rating of "Hold" by Analysts
Funds dry up for mRNA vaccines amid US political storm
Dave Gammon: mRNA technology is the future of vaccines

New MarketBeat Followers Over Time

Media Sentiment Over Time

iShares Biotechnology ETF stock logo

iShares Biotechnology ETF NASDAQ:IBB

$149.95 -2.10 (-1.38%)
Closing price 10/10/2025 04:00 PM Eastern
Extended Trading
$148.48 -1.47 (-0.98%)
As of 10/10/2025 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.

Moderna stock logo

Moderna NASDAQ:MRNA

$26.83 -0.70 (-2.54%)
Closing price 10/10/2025 04:00 PM Eastern
Extended Trading
$26.52 -0.31 (-1.15%)
As of 10/10/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.